Literature DB >> 12714872

Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins.

Eva Palmgren1, Bengt Widgren, Mattias Aurell, Hans Herlitz.   

Abstract

OBJECTIVES: An enhanced sensitivity to angiotensin II in the renal circulation has been demonstrated in the pre-hypertensive phase both in the spontaneously hypertensive rat and in man. To further characterize this abnormality and the role of prostanoids, renal haemodynamics in normotensive young men with a positive (PFH) or a negative (NFH) family history of hypertension were studied.
METHODS: Renal vascular reactivity was assessed during infusion of angiotensin II with and without inhibition of prostaglandin synthesis. Normotensive men with PFH (n = 13) and with NFH (n = 10) with a mean age of 38 years were given on two different occasions: (i). angiotensin II infusion i.v. (0.1, 0.5 and 1.0 ng/kg per min) and (ii). angiotensin II infusion after inhibition of prostaglandin synthesis with indomethacin (150 mg daily three consecutive days). Glomerular filtration rate (GFR) and renal plasma flow were measured with renal clearances of chromium edetic acid and para-aminohippuric acid.
RESULTS: Before angiotensin II challenge, the groups did not differ with respect to blood pressure, body mass index, plasma renin activity, GFR, renal blood flow (RBF) or urinary sodium excretion. There was no significant difference in systolic or diastolic blood pressure response to angiotensin II between the two groups. In PFH, the lowest angiotensin II dose caused a significant decrease in RBF and increase in renal vascular resistance (RVR) from baseline (P < 0.01 for both). In NFH, only the highest angiotensin II dose produced a significant decrease in RBF and increase in RVR (P < 0.01 for both). During inhibition of prostaglandin synthesis, all three angiotensin II doses caused a significant decrease in RBF (P < 0.02) and increase in RVR (P < 0.02) also in NFH. The renal haemodynamic difference between PFH and NFH was thus eliminated.
CONCLUSIONS: These findings indicate that young human subjects with a positive family history of hypertension have a defective vasodilator prostaglandin system, which is responsible for increased renal vascular sensitivity to angiotensin II. Enhanced renal vasoconstriction may be an early event leading to the generation of primary hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714872     DOI: 10.1097/00004872-200305000-00022

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Nonmodulation and essential hypertension.

Authors:  Norman K Hollenberg; Gordon H Williams
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

2.  The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.

Authors:  T M MacDonald; D Richard; K Lheritier; G Krammer
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

Review 3.  Cellular mediators of renal vascular dysfunction in hypertension.

Authors:  Bharathy Ponnuchamy; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

4.  Involvement of protein kinase C-CPI-17 in androgen modulation of angiotensin II-renal vasoconstriction.

Authors:  Jin Song; Kathleen M Eyster; Curtis K Kost; Barton Kjellsen; Douglas S Martin
Journal:  Cardiovasc Res       Date:  2009-10-01       Impact factor: 10.787

5.  Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats.

Authors:  Jay S Mishra; Amar S More; Kathirvel Gopalakrishnan; Sathish Kumar
Journal:  Biol Reprod       Date:  2019-01-01       Impact factor: 4.285

6.  Endothelial Vascular Function in Hypertensive Patients After Renin-Angiotensin System Blockad.

Authors:  Leon Adriana Souza-Barbosa; S Lvia E Ferreira-Melo; Samira Ubaid-Girioli; Eduardo Arantes Nogueira; Juan Carlos Yugar-Toledo; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-11       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.